Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 4
4 · Artiva Biotherapeutics, Inc. · Filed Jul 22, 2024
Insider Transaction Report
Form 4
Transactions
- Conversion
Series B Preferred Stock
2024-07-22−145,089→ 0 total→ Common Stock (145,089 underlying) - Conversion
Common Stock
2024-07-22+145,089→ 145,089 total - Other
Common Stock
2024-07-22$10.20/sh+49,019$499,994→ 194,108 total
Footnotes (2)
- [F1]Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
- [F2]Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.